ReviewJournal of clinical neurology (Seoul, Korea)2026
α-Synuclein Real-Time Quaking-Induced Conversion Assay as a Biomarker for Parkinson's Disease: Clinical Implications and Perspectives.
Review in Journal of clinical neurology (Seoul, Korea), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Parkinson's disease (PD) has traditionally been diagnosed through clinical motor symptoms and the postmortem identification of pathological α-synuclein aggregates in Lewy bodies. The focus of diagnostic paradigms has recently moved from clinical approaches toward biological measures. The cerebrospinal-fluid-based real-time quaking-induced conversion (RT-QuIC) assay demonstrates high sensitivity and specificity, significantly enhancing its diagnostic accuracy. Although the RT-QuIC assay has not yet been fully integrated into clinical practice, rapid increases in its application have made it essential to diagnostic protocols. This review examines the development, current applications, and efficacy of the RT-QuIC assay in PD, dementia with Lewy bodies, multiple-system atrophy, prodromal conditions, and elucidating clinical-pathological discrepancies. The findings can provide clear guidance for clinicians and researchers, facilitate accurate interpretations of RT-QuIC results, support informed clinical decision-making, and ultimately improve diagnostic precision and personalized management strategies across the spectrum of synucleinopathies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.